China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Shuanghe Huali passed a compliance inspection for good manufacturing practices.
The inspection was conducted by the Henan Provincial Medical Products Administration on Shuanghe Huali's production site at 369 Qinggong Road in China's Henan province. The products inspected included glucose, sodium chloride, and glucose-sodium chloride injections.
Shares of the pharmaceutical company closed 3% higher Monday.